Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN)

Cybin Inc (CYBN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 142,298
  • Shares Outstanding, K 166,120
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,960 K
  • 60-Month Beta 1.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.64
Trade CYBN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.25
  • Most Recent Earnings -0.06 on 08/08/22
  • Next Earnings Date 08/12/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.07
  • Number of Estimates 4
  • High Estimate -0.05
  • Low Estimate -0.09
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5000 +60.00%
on 07/26/22
0.9000 -11.11%
on 08/12/22
+0.2267 (+39.54%)
since 07/12/22
3-Month
0.3903 +104.97%
on 05/13/22
0.9000 -11.11%
on 08/12/22
+0.3801 (+90.52%)
since 05/12/22
52-Week
0.3903 +104.97%
on 05/13/22
2.8800 -72.22%
on 08/31/21
-1.4200 (-63.96%)
since 08/12/21

Most Recent Stories

More News
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant...

MMED.NE : 0.930 (+16.25%)
CYBN.NE : 1.020 (-6.42%)
OPTI.CN : 0.370 (-2.63%)
OPTHF : 0.2875 (-7.79%)
ATAI : 4.58 (+3.39%)
MNMD : 0.7256 (+11.58%)
CYBN : 0.8000 (-6.61%)
ENVB : 6.69 (-1.33%)
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

/PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of...

OPTI.CN : 0.370 (-2.63%)
OPTHF : 0.2875 (-7.79%)
ATAI : 4.58 (+3.39%)
MNMD : 0.7256 (+11.58%)
CYBN : 0.8000 (-6.61%)
ENVB : 6.69 (-1.33%)
Cybin (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced an at-the-market equity program allowing the company to issue...

CYBN.NE : 1.020 (-6.42%)
CYBN : 0.8000 (-6.61%)
Cybin Announces Up to USD$35 Million At-The-Market Equity Program

Cybin Inc. ( NEO: CYBN ) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, announced today that it...

CYBN.NE : 1.020 (-6.42%)
CYBN : 0.8000 (-6.61%)
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today reported unaudited financial...

CYBN.NE : 1.020 (-6.42%)
CYBN : 0.8000 (-6.61%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate CYB004 Clinical Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, has completed the acquisition...

CYBN.NE : 1.020 (-6.42%)
CYBN : 0.8000 (-6.61%)
ENBI.CN : 0.080 (-5.88%)
ENTBF : 0.0596 (-14.86%)
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Canaccord Genuity Conference

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting at the 42nd annual Canaccord Genuity Growth Conference;...

CYBN.NE : 1.020 (-6.42%)
CYBN : 0.8000 (-6.61%)
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference

Cybin Inc. ( NEO:CYBN ) ( NYSE American:CYBN ) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce...

CYBN : 0.8000 (-6.61%)
CYBN.NE : 1.020 (-6.42%)
Cybin (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled its annual shareholder meeting. The company’s 2022 Annual...

CYBN.NE : 1.020 (-6.42%)
CYBN : 0.8000 (-6.61%)
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...

CYBN.NE : 1.020 (-6.42%)
SILO : 0.1325 (-4.81%)
FTRP : 0.8500 (unch)
FTRP.TO : 1.11 (+0.91%)
ATAI : 4.58 (+3.39%)
CYBN : 0.8000 (-6.61%)
ENBI.CN : 0.080 (-5.88%)
ENTBF : 0.0596 (-14.86%)
CMPS : 18.35 (+5.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 1.0067
2nd Resistance Point 0.9533
1st Resistance Point 0.8767
Last Price 0.8000
1st Support Level 0.7467
2nd Support Level 0.6933
3rd Support Level 0.6167

See More

52-Week High 2.8800
Fibonacci 61.8% 1.9289
Fibonacci 50% 1.6352
Fibonacci 38.2% 1.3414
Last Price 0.8000
52-Week Low 0.3903

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar